Rapamycin-conditioned dendritic cells activated with monophosphoryl lipid A promote allograft acceptance <i>in vivo</i>
dc.contributor.author | Campos-Acuna, Javier | |
dc.contributor.author | Perez, Francisco | |
dc.contributor.author | Narvaez, Edgar | |
dc.contributor.author | Campos-Mora, Mauricio | |
dc.contributor.author | Gajardo, Tania | |
dc.contributor.author | Catalan, Diego | |
dc.contributor.author | Aguillon, Juan C. | |
dc.contributor.author | Pino-Lagos, Karina | |
dc.date.accessioned | 2025-01-23T21:37:38Z | |
dc.date.available | 2025-01-23T21:37:38Z | |
dc.date.issued | 2015 | |
dc.description.abstract | Aim: To date, there is no human dendritic cell (DC) based therapy to prevent allograft rejection in transplanted patients. Here, we evaluate a potential protocol using a murine in vivo transplant model. Materials & methods: We generated murine bone marrow-derived DCs (BM-DCs), modulated with rapamycin (Rapa) and activated with monophosphoryl lipid A (Rapamycin-treated and monophosphoryl lipid A-matured DCs [Rapa-mDCs]). DCs phenotype was evaluated by flow cytometry, cytokine production by ELISA and their T-cell stimulatory ability was tested in co-cultures with CD4(+) T cells. Using an in vivo skin graft model, we evaluated DCs tolerogenicity. Results: In vitro, Rapa-mDCs exhibit a semi-mature phenotype given by intermediate levels of co-stimulatory molecules and cytokines, and inhibit CD4(+) T-cell proliferation. In vivo, skin-grafted mice treated with Rapa-mDCs show high allograft survival, accumulation of Foxp3(+) Tregs and cytokine pattern modification. Conclusion: Rapa-mDCs re-educate the inflammatory microenvironment, promoting skin-allograft survival. | |
dc.fuente.origen | WOS | |
dc.identifier.doi | 10.2217/imt.14.116 | |
dc.identifier.eissn | 1750-7448 | |
dc.identifier.issn | 1750-743X | |
dc.identifier.uri | https://doi.org/10.2217/imt.14.116 | |
dc.identifier.uri | https://repositorio.uc.cl/handle/11534/101579 | |
dc.identifier.wosid | WOS:000350395600004 | |
dc.issue.numero | 2 | |
dc.language.iso | en | |
dc.pagina.final | 110 | |
dc.pagina.inicio | 101 | |
dc.revista | Immunotherapy | |
dc.rights | acceso restringido | |
dc.subject | cellular therapy | |
dc.subject | dendritic cells | |
dc.subject | regulatory T cells | |
dc.subject | tolerance | |
dc.subject.ods | 03 Good Health and Well-being | |
dc.subject.odspa | 03 Salud y bienestar | |
dc.title | Rapamycin-conditioned dendritic cells activated with monophosphoryl lipid A promote allograft acceptance <i>in vivo</i> | |
dc.type | artículo | |
dc.volumen | 7 | |
sipa.index | WOS | |
sipa.trazabilidad | WOS;2025-01-12 |